化学療法市場 - 世界の産業規模、シェア、動向、機会、予測：種類別、適応症別、剤形別、投与経路別、エンドユーザー別、地域別、競合別、2020年～2030年

世界の化学療法市場は、2024年に82億6,000万米ドルと評価され、予測期間では2030年までCAGR 8.51％で目覚ましい成長を予測されています。

世界保健機関（WHO）の発表によると、がんは世界第2位の死亡原因であり、2018年の死亡者数は960万人と推定されています。がん罹患率の上昇を考えると、化学療法の医薬品に対する需要は高まると思われます。化学療法は、体内で急速に分裂する細胞を標的にして排除する強力な化学物質を利用したがん治療法です。がん細胞の数を減らし、がんの進行を妨げ、腫瘍を縮小させる効果が証明されています。例えば、WHO2025によると、国際がん研究機関（IARC）は、世界のがん罹患率の上昇を報告しており、十分な治療を受けられない人々が最も影響を受けています。115カ国を対象とした調査では、ほとんどの国が国民皆保険制度の中で優先されるがんや緩和ケアに十分な資金を提供していないことが明らかになりました。この調査結果は、より強力な医療制度への投資を通じて、世界のがん医療の不公平に対処する緊急の必要性を強調しています。

化学療法は、単独または併用で投与されることが多く、広範ながんに対する汎用性の高い治療手段です。一次治療または単独治療として、隠れているがん細胞を除去し、放射線や手術などの他の治療に備えます。また、がん細胞を選択的に標的とすることで、がんに関連する徴候や症状を緩和することもできます。

主な市場促進要因

がん罹患率の上昇

主な市場課題

治療費の高騰

主な市場動向

革新的技術の開発

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の化学療法市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 種類別（アルキル化剤、代謝拮抗剤、抗腫瘍抗生物質、ホルモン、モノクローナル抗体、その他）
  • 適応症別（腫瘍学/がん、骨髄疾患、免疫系疾患、その他）
  • 剤形別（カプセル、錠剤、注射剤、その他）
  • 投与経路別（経口、非経口、その他）
  • エンドユーザー別（病院、専門クリニック、その他）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 北米の化学療法市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の化学療法市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋地域の化学療法市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米の化学療法市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの化学療法市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 合併と買収

第13章 世界の化学療法市場：SWOT分析

第14章 競合情勢

• F. Hoffmann-La Roche Ltd.
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Sanofi
• Pfizer Inc.
• GlaxoSmithKline plc
• Novartis AG
• Bayer AG
• Eli Lilly and Company
• Merck & Co., Inc.

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Chemotherapy Market was valued at USD 8.26 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 8.51% through 2030. Cancer, as stated by the World Health Organization (WHO), is the second leading cause of mortality worldwide, resulting in an estimated 9.6 million deaths in 2018. Given the rising cancer rates, there will be an increased demand for chemotherapy medications. Chemotherapy is a cancer treatment approach that utilizes potent chemicals to target and eliminate rapidly dividing cells within the body. It has proven efficacy in reducing cancer cell count, impeding cancer progression, and shrinking tumors. For instance, according to WHO 2025, the International Agency for Research on Cancer (IARC) reported a rising global cancer burden, with underserved populations most affected. A survey across 115 countries revealed that most do not adequately fund priority cancer and palliative care within universal health coverage. The findings underscore the urgent need to address cancer care inequities worldwide through stronger health system investments.

Chemotherapy, often administered alone or in combination, is a versatile treatment modality for a wide range of cancers. It serves as a primary or sole treatment, eliminating hidden cancer cells and preparing patients for other interventions such as radiation or surgery. It can be employed to alleviate cancer-related signs and symptoms by selectively targeting cancer cells.

Key Market Drivers

Rising Incidences of Cancers

The increasing prevalence of cancer is projected to drive the growth rate of the chemotherapy drug market. According to NIH 2025, incidence rates of certain cancers have risen among individuals under age 50. However, despite this increase, overall cancer-related deaths in younger populations have not shown a corresponding rise. This suggests improvements in early detection, treatment options, and awareness, highlighting the importance of continued research and personalized care for younger cancer patients. Chemotherapy, often used in conjunction with other cancer treatments, remains the predominant approach to cancer treatment. Neo-adjuvant chemotherapy refers to chemotherapy administered prior to surgery and radiation therapy to reduce tumor size, while adjuvant chemotherapy is administered after surgery or radiation therapy to further shrink the tumor.

Key Market Challenges

High Cost of Treatment

The high cost associated with chemotherapy drugs poses a significant obstacle to the growth of the market. High chemotherapy costs can create financial barriers for patients, leading to delayed or deferred treatment, non-adherence to prescribed regimens, and reduced treatment effectiveness. Patients with limited financial resources may face disparities in accessing chemotherapy treatments, exacerbating existing healthcare inequalities. High costs can influence patients' treatment decisions, potentially leading to suboptimal choices based on financial considerations rather than medical necessity. The financial strain of chemotherapy can lead to reduced treatment access, particularly for uninsured or underinsured patients. The shortage of skilled professionals and inadequate healthcare infrastructure in developing economies present challenges to the chemotherapy drug market. The side effects of these drugs, including heart problems, decreased red blood cell count, fatigue, weight loss, hair loss, diarrhea, reduced lung, kidney, and liver function, decreased bone density, and limited awareness among the public, act as restraints and further hinder the market.

Key Market Trends

Development of Innovative Technology

Chemotherapy has played a pivotal role in extending the lifespan of cancer patients, surpassing their expected survival by several years. The latest breakthrough in the field of chemotherapy involves the administration of specially designed nanoparticles containing cancer-fighting medications, which selectively target affected areas while sparing healthy cells. This innovative approach has demonstrated remarkable efficacy in eradicating malignant cells while preserving surrounding healthy tissue. By utilizing photon lasers, medical professionals are able to precisely monitor the release, duration, and distribution of these medication-loaded nanoparticles within the patient's body. Excitingly, the University of California, Los Angeles, is currently conducting a clinical trial to evaluate the effectiveness of this approach, which has shown promising outcomes in the treatment of early-stage cancer patients. With its imminent entry into the chemotherapeutic market, this groundbreaking technique holds great potential for transforming cancer treatment.

Key Market Players

• Hoffmann-La Roche Ltd.
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Sanofi
• Pfizer Inc.
• GlaxoSmithKline plc
• Novartis AG
• Bayer AG
• Eli Lilly and Company
• Merck & Co., Inc.

Report Scope:

In this report, the Global Chemotherapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Chemotherapy Market, By Type:

• Alkylating Agents
• Anti-metabolites
• Anti-Tumor Antibiotics
• Hormones
• Monoclonal Antibodies
• Others

Chemotherapy Market, By Indication:

• Oncology/Cancer
• Bone Marrow Diseases
• Immune System Disorders
• Others

Chemotherapy Market, By Dosage Form:

• Capsule
• Tablets
• Injections
• Others

Chemotherapy Market, By Route of Administration:

• Oral
• Parenteral
• Others

Chemotherapy Market, By End User:

• Hospitals
• Specialty Clinics
• Others

Chemotherapy Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Chemotherapy Market.

Available Customizations:

Global Chemotherapy market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Chemotherapy Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Alkylating Agents, Anti-metabolites, Anti-Tumor Antibiotics, Hormones, Monoclonal Antibodies, Others)
  • 5.2.2. By Indication (Oncology/Cancer, Bone Marrow Diseasestype, Immune System Disorders, Others)
  • 5.2.3. By Dosage Form (Capsule, Tablets, Injections, Others)
  • 5.2.4. By Route of Administration (Oral, Parenteral, Others)
  • 5.2.5. By End User (Hospitals, Specialty Clinics, Others)
  • 5.2.6. By Region
  • 5.2.7. By Company (2024)
• 5.3. Market Map

6. North America Chemotherapy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Indication
  • 6.2.3. By Dosage Form
  • 6.2.4. By Route of Administration
  • 6.2.5. By End Users
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Chemotherapy Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Indication
      • 6.3.1.2.3. By Dosage Form
      • 6.3.1.2.4. By Route of Administration
      • 6.3.1.2.5. By End Users
  • 6.3.2. Canada Chemotherapy Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Indication
      • 6.3.2.2.3. By Dosage Form
      • 6.3.2.2.4. By Route of Administration
      • 6.3.2.2.5. By End Users
  • 6.3.3. Mexico Chemotherapy Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Indication
      • 6.3.3.2.3. By Dosage Form
      • 6.3.3.2.4. By Route of Administration
      • 6.3.3.2.5. By End Users

7. Europe Chemotherapy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Indication
  • 7.2.3. By Dosage Form
  • 7.2.4. By Route of Administration
  • 7.2.5. By End Users
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Chemotherapy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Indication
      • 7.3.1.2.3. By Dosage Form
      • 7.3.1.2.4. By Route of Administration
      • 7.3.1.2.5. By End Users
  • 7.3.2. United Kingdom Chemotherapy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Indication
      • 7.3.2.2.3. By Dosage Form
      • 7.3.2.2.4. By Route of Administration
      • 7.3.2.2.5. By End Users
  • 7.3.3. Italy Chemotherapy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Indication
      • 7.3.3.2.3. By Dosage Form
      • 7.3.3.2.4. By Route of Administration
      • 7.3.3.2.5. By End Users
  • 7.3.4. France Chemotherapy Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Indication
      • 7.3.4.2.3. By Dosage Form
      • 7.3.4.2.4. By Route of Administration
      • 7.3.4.2.5. By End Users
  • 7.3.5. Spain Chemotherapy Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Indication
      • 7.3.5.2.3. By Dosage Form
      • 7.3.5.2.4. By Route of Administration
      • 7.3.5.2.5. By End Users

8. Asia-Pacific Chemotherapy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Indication
  • 8.2.3. By Dosage Form
  • 8.2.4. By Route of Administration
  • 8.2.5. By End Users
  • 8.2.6. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Chemotherapy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Indication
      • 8.3.1.2.3. By Dosage Form
      • 8.3.1.2.4. By Route of Administration
      • 8.3.1.2.5. By End Users
  • 8.3.2. India Chemotherapy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Indication
      • 8.3.2.2.3. By Dosage Form
      • 8.3.2.2.4. By Route of Administration
      • 8.3.2.2.5. By End Users
  • 8.3.3. Japan Chemotherapy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Indication
      • 8.3.3.2.3. By Dosage Form
      • 8.3.3.2.4. By Route of Administration
      • 8.3.3.2.5. By End Users
  • 8.3.4. South Korea Chemotherapy Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Indication
      • 8.3.4.2.3. By Dosage Form
      • 8.3.4.2.4. By Route of Administration
      • 8.3.4.2.5. By End Users
  • 8.3.5. Australia Chemotherapy Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Indication
      • 8.3.5.2.3. By Dosage Form
      • 8.3.5.2.4. By Route of Administration
      • 8.3.5.2.5. By End Users

9. South America Chemotherapy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Indication
  • 9.2.3. By Dosage Form
  • 9.2.4. By Route of Administration
  • 9.2.5. By End Users
  • 9.2.6. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Chemotherapy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Indication
      • 9.3.1.2.3. By Dosage Form
      • 9.3.1.2.4. By Route of Administration
      • 9.3.1.2.5. By End Users
  • 9.3.2. Argentina Chemotherapy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Indication
      • 9.3.2.2.3. By Dosage Form
      • 9.3.2.2.4. By Route of Administration
      • 9.3.2.2.5. By End Users
  • 9.3.3. Colombia Chemotherapy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Indication
      • 9.3.3.2.3. By Dosage Form
      • 9.3.3.2.4. By Route of Administration
      • 9.3.3.2.5. By End Users

10. Middle East and Africa Chemotherapy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Indication
  • 10.2.3. By Dosage Form
  • 10.2.4. By Route of Administration
  • 10.2.5. By End Users
  • 10.2.6. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Chemotherapy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Indication
      • 10.3.1.2.3. By Dosage Form
      • 10.3.1.2.4. By Route of Administration
      • 10.3.1.2.5. By End Users
  • 10.3.2. Saudi Arabia Chemotherapy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Indication
      • 10.3.2.2.3. By Dosage Form
      • 10.3.2.2.4. By Route of Administration
      • 10.3.2.2.5. By End Users
  • 10.3.3. UAE Chemotherapy Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Indication
      • 10.3.3.2.3. By Dosage Form
      • 10.3.3.2.4. By Route of Administration
      • 10.3.3.2.5. By End Users

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions

13. Global Chemotherapy Market: SWOT Analysis

14. Competitive Landscape

• 14.1. F. Hoffmann-La Roche Ltd.
• 14.2. Mylan N.V.
• 14.3. Teva Pharmaceutical Industries Ltd.
• 14.4. Sanofi
• 14.5. Pfizer Inc.
• 14.6. GlaxoSmithKline plc
• 14.7. Novartis AG
• 14.8. Bayer AG
• 14.9. Eli Lilly and Company
• 14.10. Merck & Co., Inc.

15. Strategic Recommendations

16. About Us & Disclaimer